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and Neeraj Dhaun 1,3,*
Abstract
Objective. ANCA-associated vasculitis (AAV) is a small vessel vasculitis that commonly presents in the elderly. However,
there are few long-term outcome data for these patients. Here, we assessed long-term outcomes in a single-centre cohort
of elderly patients with AAV. Additionally, we tested whether a pre-morbid frailty score could aid prognosis.
Methods. Using a prospectively-compiled dataset, we investigated patients over the age of 65 who presented with AAV
between 2005 and 2017 to a regional vasculitis centre. We used a Cox model to determine the factors associated with
mortality. We also compared outcomes in pre-specified subgroups stratified by baseline frailty score, ANCA serotype
and induction immunosuppression (with cyclophosphamide, rituximab or mycophenolate mofetil used as the main gluco-
corticoid-sparing agent).
Results. 83 patients were included in the study and were followed for a median of 1203 days. Median age was 74 years
(range 6592). Two- and five-year survival in the overall cohort were 83% (95% CI 75, 92%) and 75% (95% CI 65, 86%),
respectively. The median cumulative dose of oral prednisolone was 2030 mg during the first three months. Only one
patient received intravenous glucocorticoids. Age, frailty score and CRP at presentation were independently associated
with mortality; all deaths occurred in patients aged over 75 at presentation. Patients treated with a cyclophosphamide-
based induction regimen tended to be younger than those treated with rituximab or mycophenolate mofetil. Survival was
better in the cyclophosphamide-treated group.
Conclusion. In the contemporary era, the overall prognosis of AAV in elderly patients is good. Baseline frailty asso-
ciates with disease outcomes including mortality. A low-dose glucocorticoid regimen (avoiding intravenous methylpred-
nisolone) can be used to treat AAV effectively in elderly patients.
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Rheumatology key messages
. A glucocorticoid-sparing regimen can give good long-term clinical outcomes in ANCA vasculitis in the elderly.
. Age, frailty score and CRP are associated with mortality in elderly patients with ANCA vasculitis.
. Patients aged >75, or with a Rockwood Clinical Frailty score of 54, have higher mortality.
Introduction
ANCA-associated vasculitis (AAV) is a small-vessel vas-
culitis that may present at any age. The incidence peaks
in the seventh and eighth decades [13]. Elderly pa-
tients—often defined as being aged over 65—are particu-
larly vulnerable to the adverse effects of the disease and
of the immunosuppression used to treat it [4]. Previous
studies have shown that increasing age and decreasing
performance status are associated with poor outcomes.
However, these studies were conducted in distinct pa-
tient sub-groups, such as those with ANCA-associated
glomerulonephritis, and in an era pre-dating the wide-
spread use of rituximab [58]. Also, elderly patients are
under-represented in randomized controlled trials of in-
duction immunosuppression in AAV. For example, mean
participant ages in the CYCLOPS, RAVE and MYCYC
trials were 57, 53 and 60 years, respectively [911].
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It is important to accurately define the outcomes of AAV
in the elderly so that doctors, patients and their families
are able to make informed choices about treatment. We
therefore aimed to assess long-term outcomes in an un-
selected ‘real-world’ cohort of patients with AAV present-
ing at the age of 65 years and over. We tested the
hypothesis that a baseline frailty score would provide
prognostic information.
Methods
Patient population and data collection
We recruited consecutive patients with a diagnosis of AAV
who presented to our vasculitis service at age 65 or over
from 1 July 2005 to 9 November 2017. The Royal Infirmary
of Edinburgh provides a vasculitis service for a population
of around one million. We have previously described the
structure of our clinical service [12]. The majority of new
patients are referred from secondary care; around 20%
are referred from general practice or accident & emer-
gency. In addition to referrals made on the basis of a clin-
ical suspicion of ANCA vasculitis, all new positive ANCA
results in Lothian are reflexed to a senior vasculitis clin-
ician who then discusses the result with the physician who
requested the test. Clinical and laboratory data were col-
lected prospectively. eGFR was calculated using the
CKD-EPI equation. Vasculitis disease activity was as-
sessed at each clinic visit. We recorded the cumulative
dose of glucocorticoids administered during the first
3 months. The following adverse events were recorded:
infections requiring hospitalization and/or intravenous
antibiotic therapy, fractures, new diagnosis of malignancy,
cardiovascular/venous thromboembolic events and
death. As this analysis formed part of a clinical service
evaluation, we did not obtain specific ethical approval or
individual patient consent.
Frailty score
Baseline frailty was scored using a validated clinical scale:
the nine-point Canadian Study on Health and Ageing
Clinical Frailty Scale, also known as Rockwood’s Clinical
Frailty Scale (RCFS). This tool has been shown to have
good inter-observer variability and associates with hard
outcomes in a range of diseases [1318]. As well as eval-
uating the potential utility of the RCFS on the nine-point
scale, we also conducted a pre-specified analysis com-
paring outcomes in patients deemed to be ‘less frail’ or
‘more frail’ at baseline (RCFS 43 vs 54). This RCFS
threshold was chosen as it is the point at which symptoms
begin to limit activities and is thus a relatively sensitive
measure of vulnerability and frailty. A score of 3 is given
to patients who are, ‘Managing Well  People whose med-
ical problems are well controlled, but are not regularly
active beyond routine walking’. A score of 4 is for those
who are, ‘Vulnerable  While not dependent on others for
daily help, often symptoms limit activities. A common
complaint is being ‘‘slowed up,’’ and/or being tired
during the day’.
Disease and treatment definitions
Remission was defined as clinically silent disease in a pa-
tient taking no more than 7.5 mg prednisolone per day
[19]. In this context, clinically silent disease was defined
as the absence of symptoms or signs attributable to vas-
culitis disease activity. Relapse was defined as a change
in symptoms or signs that—after appropriate investiga-
tion—was likely to be attributable to vasculitis disease ac-
tivity and not to alternative pathology such as infection. In
almost all instances this prompted an escalation in im-
munosuppression. Induction regimens were classified as
‘cyclophosphamide-based’ if the patient received cyclo-
phosphamide exclusively, ‘rituximab-based’ if the patient
received rituximab exclusively or in conjunction with up to
two doses of intravenous cyclophosphamide, and ‘MMF-
based’ if patients received mycophenolate mofetil (MMF)
but neither cyclophosphamide nor rituximab (with or with-
out glucocorticoids).
Oral prednisolone was administered according to a regi-
men tailored to the individual patient. For most patients, this
was initiated at a daily dose of 1 mg per kg body weight (usu-
ally no more than 60 mg). The dose was then reduced ac-
cording to the regimen outlined in Supplementary Table S1,
available at Rheumatology online. This was tailored accord-
ing to patient and disease characteristics (age, frailty, co-
morbidities, infections, severity of vasculitis etc.). We do not
routinely prescribe intravenous glucocorticoids at presenta-
tion (for patients of any age).
Statistical analysis
Statistical analysis was conducted in R (version 3.5.3) [20].
Unless stated otherwise, data are presented as median
and interquartile range. Non-parametric data were com-
pared by the Wilcoxon rank sum test. Survival analysis
was performed using the Survminer package [21].
Mortality risk was compared between groups by deter-
mining Cox proportional hazard ratios with associated
95% CIs, after first evaluating Schoenfield residuals to
confirm that the proportional hazards assumption was
satisfied. We adjusted for frailty, age, sex, ANCA status,
eGFR and CRP, all assessed at baseline (i.e. time of
patient presentation). In the adjusted model, eGFR was
treated as a continuous variable as it demonstrated linear-
ity. For eGFR, the hazard was calculated in decile (10 ml/
min) rather than 1 ml/min increments to better reflect clin-
ically meaningful incremental changes in renal function.
CRP did not demonstrate linearity and was therefore ana-
lysed as a categorical variable using thresholds of 25, 50,
100 and 150 mg/l, chosen to correspond to clinically
meaningful increments in the inflammatory response.
Results
Baseline demographic and disease characteristics
Eighty-three patients were included and were followed up
for a median of 1203 days (interquartile range (IQR)
6642166). Baseline data are presented in Table 1. The
median age was 74 years (Supplementary Fig. S1A, avail-
able at Rheumatology online); 63% of patients were
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female. Fifty-seven patients were positive for anti-MPO
ANCA, 22 for anti-proteinase 3 (PR3) ANCA, two had
both and two were ANCA-negative. The distribution of
frailty scores is shown in Supplementary Fig. S1B, avail-
able at Rheumatology online.
Fifty-seven patients (68%) had involvement of more
than one organ at diagnosis. Around 50% of patients
had respiratory system involvement at presentation but
only five patients (6% of the whole cohort) had alveolar
haemorrhage.
Treatment
Eighty patients (96%) were treated with oral prednisolone.
The median cumulative dose of prednisolone adminis-
tered during the first 3 months was 2030 mg (IQR
17852167). There was no significant difference in the cu-
mulative glucocorticoid exposure in the more and less frail
groups (Supplementary Fig. S1C, available at
Rheumatology online). Only one patient was prescribed
intravenous methylprednisolone. Three patients were
treated with an entirely glucocorticoid-free regimen.
Thirty-two (39%) patients were treated with a cyclophos-
phamide-based induction regime, 31 (37%) with a rituxi-
mab-based regime, 10 (12%) with MMF and 10 (12%)
with alternative glucocorticoid-sparing agents (e.g. metho-
trexate or no steroid-sparing agent). Twenty-two patients
received adjunctive plasmapheresis; these patients all had
aggressive disease (as assessed clinically and from the
kidney biopsy) or alveolar haemorrhage. We have previously
described our criteria for administering plasmapheresis (in
the pre-PEXIVAS era) [12]. All patients received co-trimoxa-
zole for Pneumocystis jirovecii prophylaxis. Median duration
of the presenting hospital admission was 16 days (IQR
827 days).
Outcomes
During follow-up, 21 patients (25%) died; median time to
death was 453days (IQR 1761090). Two-year and five-year
survival in the whole cohort were 83% (95% CI 75, 92%) and
75% (95% CI 65, 86%), respectively (Fig. 1). Remission was
achieved in 70 patients after a median of 125days (IQR
92179). Disease relapsed in 16 of these patients after a
median of 632days (IQR 326915) from the date of remission.
Five patients had more than one disease relapse.
Adverse events
Seventy-four adverse events were recorded. The most
common adverse event was infection requiring
TABLE 1 Baseline characteristics of the study cohort
ANCA serotype MPO (n=57) PR3 (n=22) Other (n=4) Overall (n=83)
Demographic data
Age (years) 73 (68, 80) 74 (66, 78) 82 (77, 84) 74 (68, 80)
Female 36 (63%) 13 (59%) 3 (75%) 52 (63%)
Weight (kg) 72 (60, 85) 74 (67, 83) 62 (61, 62) 72 (60, 84)
RCFS 3.00 3.00 3.00 3.00
(2.75, 4.00) (3.00, 4.00) (2.75, 3.75) (3.00, 4.00)
Laboratory data
Creatinine (microM) 233 (142, 345) 215 (89, 357) 130 (63, 212) 221 (130, 338)
eGFR (ml/min) 38 (22, 70) 40 (17, 90) 74 (40, 105) 40 (22, 77)
U.PCR (mg/mmol) 109 (47, 274) 211 (33, 283) 47 (36, 310) 121 (45, 285)
Haemoglobin (g/L) 96 (83, 106) 94 (84, 107) 112 (94, 129) 96 (84, 107)
Albumin (g/L) 27 (21, 33) 26 (21, 31) 28 (24, 32) 27 (21, 33)
CRP (mg/L) 56 (14, 112) 70 (26, 144) 38 (22, 58) 58 (15, 112)
Organ involvement
Kidney 53 (91%) 18 (86%) 2 (50%) 73 (83%)
Lung 27 (47%) 13 (62%) 2 (50%) 42 (51%)
Nerve 17 (29%) 4 (19%) 2 (50%) 23 (28%)
ENT 9 (16%) 4 (19%) 1 (25%) 13 (16%)
Skin 6 (10%) 6 (29%) 0 (0%) 12 (14%)
Joints 3 (5%) 4 (19%) 0 (0%) 7 (8%)
Eyes 2 (3%) 3 (14%) 0 (0%) 5 (6%)
Pulmonary haemorrhage 2 (3%) 2 (10%) 1 (25%) 5 (6%)
Induction regimen
Glucocorticoids 57 (98%) 20 (95%) 3 (75%) 80 (96%)
Cyclophosphamide 22 (38%) 10 (48%) 0 (0%) 32 (39%)
Rituximab 24 (41%) 6 (29%) 1 (25%) 31 (37%)
MMF 10 (17%) 0 (0%) 0 (0%) 10 (12%)
Other 0 (0%) 4 (19%) 2 (50%) 6 (7%)
Plasmapheresis 15 (26%) 7 (33%) 0 (0%) 22 (27%)
Data are median (IQR) unless stated otherwise. RCFS, Rockwood Clinical Frailty Scale; eGFR, estimated glomerular filtration
rate; U.PCR, urine protein : creatinine ratio.
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hospitalization (44 events). Other adverse events were
venous thromboembolism (9), skeletal fracture (8), acute
coronary syndrome (6) and new malignancy (6).
Factors associated with mortality
In order to identify the factors that are associated with
mortality, we constructed a Cox proportional hazards
model. Frailty score, age and very high baseline CRP (>
149 mg/l) were independently associated with increased
risk of death (Fig. 2). Indeed, all of the deaths occurred in
patients aged over 75.
Associations with ANCA serotype
As expected, there were differences between MPO- and
PR3-positive patients at baseline, with PR3-positive pa-
tients being more likely to have lung, skin, joint and eye
involvement (Table 1). PR3-positive patients were also
more likely to have alveolar haemorrhage (10% vs 4%).
There were no differences in mortality or time-to-remis-
sion between PR3- and MPO-positive patients but PR3-
positive patients had a higher rate of relapse and relapsed
earlier (Fig. 3).
Associations with baseline frailty score
Baseline frailty was associated with mortality. The un-
adjusted hazard ratio was 2.07 (95% CI 1.50, 2.87), mean-
ing that for each additional point on the frailty score, the
risk of death approximately doubled. In a model adjusted
for potentially confounding variables (age, sex, ANCA
status, eGFR and CRP), the hazard ratio was 1.90
(1.033.52) (Fig. 2).
In a pre-specified analysis, we compared outcomes in
those patients with a lower vs higher baseline frailty score
(RCFS43 vs54). (This is the point at which frailty begins
to limit activity, see Methods.) Fifty-five patients were in
the less frail group; 27 were in frailer group; the remaining
patient had no baseline frailty score recorded. Mortality
was significantly higher in the frailer group. Two-year sur-
vival was 63% vs 93%; five-year survival 47% vs 90%.
There were no differences between groups in time to re-
mission or time to relapse (data not shown). There were
more adverse events in the frailer group (1.4 vs 1.1 events
per patient) and a greater proportion of patients in the
frailer group had at least one adverse event (81% vs
58%; P = 0.065 by 2 test). Patients in the frailer group
had a longer index hospital admission (23.7 ± 16.4 vs
15.0 ± 13.0 days; P = 0.02).
Associations with induction immunosuppression
regimen
The cohorts treated with cyclophosphamide, rituximab
and MMF differed in their baseline characteristics
(Table 2 and Supplementary Fig. S2, available at
Rheumatology online). Patients treated with cyclophos-
phamide tended to be younger and have better renal func-
tion at presentation. Mortality was marginally lower in the
cyclophosphamide group (Supplementary Fig. S3, avail-
able at Rheumatology online); there were no differences
between treatment groups in time to remission or time to
relapse (data not shown). The proportion of patients who
experienced at least one adverse event did not differ be-
tween groups (rituximab 61%, cyclophosphamide 75%,
MMF 70%; P = 0.501 by 2 test).
Discussion
We present the long-term outcomes of an unselected
cohort of elderly patients with AAV. Mortality and morbid-
ity outcomes were favourable, supporting the view that
there is overall benefit in treating elderly patients present-
ing with AAV. Our cohort is representative of other studies
in elderly patients with AAV, with a relatively high propor-
tion of MPO-positive disease [6, 2224]. However, our
study cohort is larger and has longer follow-up than
most published observational and interventional studies
of AAV in the elderly.
In our cohort (median age 74), two-year and five-year
survival were 83% and 75%, respectively. To put this into
context, the two-year survival of a Scottish 74-year-old is
94% in the general population [25]. For Scottish adults
with type 1 diabetes mellitus, two-year survival in this age-
group is 86% [26].
Associations with mortality
It is not surprising that increasing age was independently
associated with mortality. That a frailty score was also
associated with mortality—even after adjusting for age
and other potentially confounding variables—suggests
that this simple tool might provide useful additional infor-
mation about elderly patients with ANCA vasculitis.
Baseline frailty was associated with greater mortality,
more adverse events and a longer hospital stay. This,
therefore, has the potential to provide a free, accessible
and rapid tool to allow prognostication in elderly patients
FIG. 1 Patient survival in whole cohort (with 95% CI)
.
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presenting with AAV. Such information is invaluable to
clinicians, patients and their families when deciding
whether and how to treat their disease. Our data empha-
size that advanced care planning should be a core com-
ponent of care for frail, elderly patients presenting with
AAV, and particularly in patients aged over 75. Our data
could inform the design of future interventional
randomized controlled trials by defining a cohort of frail
elderly patients who might benefit from more conservative
(e.g. glucocorticoid-free) treatment regimens.
Induction immunosuppression
In our study, the choice of induction regimen was not
protocolised. This was selected at the discretion of a
senior vasculitis physician. We tended to use cyclophos-
phamide in patients who were younger and who had rela-
tively better renal function. The better survival in the
cyclophosphamide group is therefore likely to reflect
baseline patient characteristics rather than any effect of
the treatment itself (i.e. confounding by indication).
Nevertheless, our data demonstrate that rituximab and
MMF are useful options for treating the frail elderly in a
‘real-world’ setting. As in randomized controlled trials,
rituximab was non-inferior to cyclophosphamide at indu-
cing and maintaining disease remission and in its adverse
event profile [10].
We used a relatively low-dose glucocorticoid regime.
Our median cumulative dose of oral prednisolone was
2 g during the first three months. This equates to an
average daily dose of 22 mg. Following our typical regi-
men (Supplementary Table S1, available at Rheumatology
online), we would be predicted to prescribe a cumulative
dose of 2.1 g during the first three months. To put this in
context, the ‘predicted’ cumulative dose is 1.8 g in the
low-dose glucocorticoid arm of the PEXIVAS trial and
3.3 g in the standard-dose arm [27]. (Data on the
actual doses administered in PEXIVAS are not yet in the
public domain.) A recent study reported outcomes in 49
patients treated with a glucocorticoid-sparing regime.
Here, the investigators used a cumulative dose of <0.7 g
within the first three months [28]. However, and in contrast
to our cohort, patients in this study and in PEXIVAS were
routinely treated with intravenous methylprednisolone (up
to 3 g) at disease presentation. Therefore, our glucocortic-
oid regimen is low-dose compared with other published
observational and interventional studies. Our favourable
outcomes add to the growing weight of evidence that
glucocorticoid doses can be safely minimized in AAV.
They also suggest that— particularly in elderly patients—
intravenous methylprednisolone is not a necessary com-
ponent of induction immunosuppression for the vast ma-
jority of patients. Our findings therefore align with those of
a recent retrospective analysis of short-term outcomes in
severe renal AAV. In this group, IV methylprednisolone use
was associated with increased risks of infection and dia-
betes (and not with any differences in patient or renal sur-
vival) [29].
Strengths and limitations
The observational nature of our study has strengths and
limitations. We cannot determine the effect of any treat-
ment regimen on clinical outcome. However, as the re-
sults of randomized controlled trials are not always
borne out in ‘real-world’ clinical practice, our data provide
valuable information on disease outcomes in a contem-
porary patient cohort.
FIG. 2 Hazard of death during follow-up period
Hazard ratios (with 95% CI) were computed in a Cox proportional hazards model, adjusted for frailty, age, sex, ANCA
status, eGFR and CRP. All predictor variables were assessed at presentation. RCFS, Rockwood Clinical Frailty Scale;
eGFR, estimate glomerular filtration rate.
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Similarly, given the single-centre nature of our study,
our findings cannot be extrapolated widely without repli-
cation. Conversely, as all immunosuppression was pre-
scribed by two senior clinicians, our data are not subject
to the noise generated by inter-individual and inter-centre
variability, allowing us to resolve those patient and dis-
ease factors that influence prescribing. Moreover, the
robust systems used in our centre for prospective data
collection mean that we have a near-complete dataset.
Published trials in ANCA vasculitis tend to report out-
comes in tertiary referral centres with a specialized vas-
culitis service. This may of course bias the literature
towards more favourable outcomes (and any publication
bias might be expected to contribute further to this dis-
tortion). Our study— performed in one such specialized
vasculitis service—should be interpreted with these cav-
eats in mind. To our knowledge, the hypothesis that a
specialized vasculitis service results in better patient out-
comes has not been formally tested; this is a potentially
important topic for future research.
Other potential sources of bias in this observational
study are case ascertainment and referral bias: i.e. it is
possible that elderly and/or frail patients are less likely to
be investigated for (and therefore diagnosed with) ANCA
vasculitis. The apparent decline in the incidence of ANCA
vasculitis in patients aged over 80 suggests that our data
FIG. 3 Disease outcomes stratified by ANCA serotype
A) Time to death. B) Time to remission. C) Time to relapse.
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may be subject to such a bias (Supplementary Fig. S1,
available at Rheumatology online).
Conclusions
We have presented the long-term outcomes in an un-
selected cohort of elderly patients with AAV. Overall,
two-year and five-year survival rates were 83 and 75%,
respectively. Increasing age, frailty and very high CRP at
baseline were associated with mortality. A higher baseline
frailty score was associated with increased mortality and
more adverse events. Cyclophosphamide, rituximab and
MMF are all valid treatment options in the elderly. A low-
dose glucocorticoid regimen (in which intravenous
methylprednisolone is not routinely used) can be used to
treat AAV in elderly patients, with favourable outcomes.
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PR3 (%) 8 (26) 10 (31) 0 (0) 4 (40)
RCFS 3 (3.00, 4.00) 3 (2.00, 3.00) 3.50 (3.00, 5.00) 3.50 (3.00, 5.75)
laboratory data
Cr (microM) 264 (201, 360) 179 (86, 266) 253 (156, 336) 153 (66, 208)
eGFR (ml/min) 25 (18, 41) 47 (27, 96) 32 (24, 61) 68 (34, 104)
U.PCR (mg/mmol) 121 (50, 212) 112 (44, 284) 290 (154, 427) 260 (41, 497)
Hb (g/L) 98 (92, 105) 94 (82, 110) 92 (79, 106) 85 (84, 120)
alb (g/L) 26 (21, 32) 25 (20, 32) 29 (27, 36) 30 (25, 35)
CRP (mg/L) 61 (24, 104) 70 (14, 158) 38 (20, 62) 55 (15, 87)
Data are median (IQR) unless stated otherwise. RCFS, Rockwood Clinical Frailty Scale; eGFR, estimated glomerular filtration
rate; U.PCR, urine protein : creatinine ratio; Hb, haemoglobin.
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